Last reviewed · How we verify
Monovalent Tetanus vaccine
Monovalent Tetanus vaccine is a Toxoid vaccine Biologic drug developed by Sanofi Pasteur, a Sanofi Company. It is currently in Phase 3 development for Active immunization against tetanus.
A monovalent tetanus toxoid vaccine that stimulates the immune system to produce antibodies against tetanus toxin, providing active immunity against Clostridium tetani infection.
A monovalent tetanus toxoid vaccine that stimulates the immune system to produce antibodies against tetanus toxin, providing active immunity against Clostridium tetani infection. Used for Active immunization against tetanus.
At a glance
| Generic name | Monovalent Tetanus vaccine |
|---|---|
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Drug class | Toxoid vaccine |
| Target | Tetanus toxin (tetanospasmin) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains inactivated tetanus toxin (toxoid) that triggers a humoral immune response, leading to the production of protective antibodies against tetanus toxin. Upon exposure to C. tetani, these pre-formed antibodies neutralize the bacterial toxin and prevent tetanus disease. Monovalent formulation contains only tetanus antigen, distinguishing it from combination vaccines.
Approved indications
- Active immunization against tetanus
Common side effects
- Injection site pain or erythema
- Myalgia
- Headache
- Fever
- Fatigue
Key clinical trials
- Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PHASE3)
- Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine (PHASE3)
- Study Comparing a Tdap-IPV Combined Vaccine With a Tetanus Monovalent Vaccine in Healthy Adults (PHASE3)
- DTaP-IPV-Hep B-PRP~T Combined Vaccine Versus DTaP-IPV//PRP~T Combined Vaccine + Hep B Vaccine in Hep B Primed Infants (PHASE3)
- Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age (PHASE3)
- Immunogenicity and Safety of a Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Hib Vaccine in 13-59 Months Old Healthy Children (PHASE3)
- Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age. (PHASE3)
- Immunogenicity and Safety of Vaccinations in Immunocompromised Persons
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Monovalent Tetanus vaccine CI brief — competitive landscape report
- Monovalent Tetanus vaccine updates RSS · CI watch RSS
- Sanofi Pasteur, a Sanofi Company portfolio CI
Frequently asked questions about Monovalent Tetanus vaccine
What is Monovalent Tetanus vaccine?
How does Monovalent Tetanus vaccine work?
What is Monovalent Tetanus vaccine used for?
Who makes Monovalent Tetanus vaccine?
What drug class is Monovalent Tetanus vaccine in?
What development phase is Monovalent Tetanus vaccine in?
What are the side effects of Monovalent Tetanus vaccine?
What does Monovalent Tetanus vaccine target?
Related
- Drug class: All Toxoid vaccine drugs
- Target: All drugs targeting Tetanus toxin (tetanospasmin)
- Manufacturer: Sanofi Pasteur, a Sanofi Company — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for Active immunization against tetanus
- Compare: Monovalent Tetanus vaccine vs similar drugs
- Pricing: Monovalent Tetanus vaccine cost, discount & access